Most Read

A fully human biologic, Cosentyx is developed to directly target interleukin-17A (IL-17A), a cytokine. IL-17A is involved in the inflammation of plaque psoriasis, psoriatic arthritis (PsA), ankylosing spondylitis

Trastuzumab is a monoclonal antibody intended to treat human epidermal growth factor receptor 2 positive (HER2-positive) breast and metastatic gastric cancers. The company aims to secure EMA approval

The agreement with the Government of the UK is subject to the local authorisation of the Covid-19 pill. Previously, the UK placed an order of 250,000 Paxlovid doses.

Molnupiravir is an orally administered form of a potent ribonucleoside analogue that blocks the SARS-CoV-2 replication. It is planned to be sold under the trademark Lagevrio in the

This brings the company’s total Series A funding raised to $107m. The financing was led by Third Rock Ventures and saw participation from Smilegate Investment, Schroders Capital, Alexandria

The long-acting injectable is indicated for use in adults and adolescents who are at risk of sexually acquiring HIV and test negative for HIV-1 before initiation. The regulatory

Developed using Novavax’ recombinant nanoparticle technology, the vaccine also known as NVX-CoV2373 is a protein-based Covid-19 vaccine candidate which is engineered from the genetic sequence of the initial

A fully human monoclonal antibody, Saphnelo targets subunit 1 of the type one interferon (type 1 IFN) receptor, blocking the type 1 IFN’s activity. It has been recommended

Alpine Immune Sciences and Horizon Therapeutics have signed an exclusive licence and collaboration agreement to develop protein-based therapies to treat autoimmune and inflammatory diseases. As agreed, Horizon will